[1-amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | 1032959-78-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: [1-amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester
• 英文别名: ethyl N-[1-amino-5-[4-(trifluoromethyl)anilino]-5,6,7,8-tetrahydronaphthalen-2-yl]carbamate
• CAS: 1032959-78-6
• 化学式: C₂₀H₂₂F₃N₃O₂
• 分子量: 393.409
• InChiKey: UHYJRNROXVDZKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [1-nitro-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester 、 [3-nitro-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester 在 镍 甲醇 、 products 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 [1-amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester
  参考文献：
  名称：

  Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators

  摘要：

  本发明提供了式I的化合物，其中Ar1是一个5-至10-成员的单环或双环芳香基团，可选地被取代；其中—NR3R4基团位于NHC（═X）基团的邻位；n=1或2；X=O或S；Y是O或S；q=1或0。本发明还提供了包括式I的化合物和/或其盐、酯和前药的药物组合物。这些化合物调节钾通道的激活和失活。这些化合物可用于治疗和预防受钾离子通道调节影响的疾病和障碍，例如癫痫等。

  公开号：

  US08338487B2

文献信息

• Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
  申请人：Chen Huanming

  公开号：US20080146661A1

  公开（公告）日：2008-06-19

  This invention provides compounds of formula I where Ar 1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR 3 R 4 group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.

  这项发明提供了式I的化合物，其中Ar1是一个5到10个成员的单环或双环芳香基团，可选地取代；其中-NR3R4基团位于NHC(═X)基团的邻位；n=1或2；X=O或S；Y为O或S；q=1或0。该发明还提供了包括式I的化合物和/或其盐、酯和前药的药物组合物。这些化合物调节钾通道的激活和失活。这些化合物可用于治疗和预防受钾离子通道调节影响的疾病和紊乱，如癫痫等疾病。
• Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
  申请人：Valeant Pharmaceuticals International

  公开号：US07960436B2

  公开（公告）日：2011-06-14

  This invention provides compounds of formula I where Ar1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR3R4 group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.

  本发明提供了I式化合物，其中Ar1是一个5-到10成员的单环或双环芳香基团，可选地被取代；其中—NR3R4基团位于NHC(═X)基团的邻位；n=1或2；X═O或S；Y为O或S；q=1或0。本发明还提供了包括I式化合物及/或其盐、酯和前药的制药组合物。这些化合物调节钾通道的激活和失活。这些化合物对于治疗和预防受钾离子通道调节影响的疾病和疾患（如癫痫）是有用的。
• SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS
  申请人：Chen Huanming

  公开号：US20110207812A1

  公开（公告）日：2011-08-25

  This invention provides compounds of formula I where Ar 1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR 3 R 4 group is situated ortho to the NHC(═X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.

  本发明提供了式I的化合物，其中Ar1是一个5-至10-成员的单环或双环芳香基团，可选择性地被取代；其中—NR3R4基团位于NHC(═X)基团的邻位；n=1或2；X=O或S；Y是O或S；q=1或0。该发明还提供了包括式I的化合物和/或其盐、酯和前药的药物组合物。这些化合物调节钾通道的激活和失活。这些化合物对于治疗和预防受钾离子通道调节影响的疾病和紊乱，例如癫痫等疾病非常有用。
• US7960436B2
  申请人：——

  公开号：US7960436B2

  公开（公告）日：2011-06-14
• US8338487B2
  申请人：——

  公开号：US8338487B2

  公开（公告）日：2012-12-25